StockData
ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V. (PRQR) stock

PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 7/30
$1.10−0.05 (-4.35%)

Close on Nov 18, 2026Market cap $115.90MP/E –Yield –

ProQR Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

ProQR Therapeutics's revenue for the twelve months ending Jun 30, 2026 was €18.36M, up 11.4% year over year. For fiscal 2025 it was €15.91M, down 15.9% from the year before. The highest annual figure on record is €18.91M in fiscal 2024.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025€15.91M-15.9%
FY2024Dec 31, 2024€18.91M+190.2%
FY2023Dec 31, 2023€6.51M+81.2%
FY2022Dec 31, 2022€3.59M+169.2%
FY2021Dec 31, 2021€1.34M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026€8.76M+129.5%
Q1 FY2026Mar 31, 2026€2.03M-55.0%
Q4 FY2025Dec 31, 2025€4.69M+8.8%
Q3 FY2025Sep 30, 2025€2.88M-25.0%
Q2 FY2025Jun 30, 2025€3.82M-39.5%
Q1 FY2025Mar 31, 2025€4.52M+1.6%
Q4 FY2024Dec 31, 2024€4.31M+31.2%
Q3 FY2024Sep 30, 2024€3.84M+180.5%
Q2 FY2024Jun 30, 2024€6.31M+423.2%
Q1 FY2024Mar 31, 2024€4.45M+579.4%
Q4 FY2023Dec 31, 2023€3.28M+356.1%
Q3 FY2023Sep 30, 2023€1.37M+68.3%
Q2 FY2023Jun 30, 2023€1.21M+29.6%
Q1 FY2023Mar 31, 2023€655.00K-42.0%
Q4 FY2022Dec 31, 2022€720.00K+201.3%
Q3 FY2022Sep 30, 2022€814.00K-6.7%
Q2 FY2022Jun 30, 2022€930.00K+282.7%
Q1 FY2022Mar 31, 2022€1.13M–
Q4 FY2021Dec 31, 2021€239.00K–
Q3 FY2021Sep 30, 2021€872.00K–
Q2 FY2021Jun 30, 2021€243.00K–

More ProQR Therapeutics figures

See a number that looks wrong?